CB Insights
Technology Market Intelligence
Technology Market Intelligence
Threshold Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of small molecule therapeutics based on Metabolic Targeting, an approach that offers broad potential to treat most solid tumors and certa...Show all
Company (Merged)
Phone: 650-474-8200
1300 Seaport Boulevard
Suite 500
Redwood City, 94063
California, United States
| Total Funding | Date of Last Funding | |
|---|---|---|
| Threshold Pharmaceuticals | $69.1M | Aug 2, 2017 |
| Trevena | $188.5M | Jan 31, 2014 |
| Arcion Therapeutics | $17M | Oct 1, 2012 |
| See all 74 competitors | ||
| Per Week | Per Month | Per 6 Months | Per Year | |
|---|---|---|---|---|
| Rank | Login to see details | |||
| Page Views Per Million | Login to see details | |||
| Page Views Per User | Login to see details | |||
| Reach Per Million | Login to see details | |||
| Title | Application Date | Patent Date | Status (Patent / Application) |
|---|---|---|---|
| Predictive biomarker for hypoxia-activated prodrug therapy | Nov 18, 2015 | Sep 01, 2020 | Patent |
| Th-302 solid forms and methods related thereto | Jul 15, 2015 | Nov 20, 2018 | Patent |
| Administration of hypoxia activated prodrugs in combination with chk1 inhibitors for treating cancer | Dec 20, 2012 | Feb 09, 2016 | Patent |
| Phosphoramidate alkylator prodrugs | Dec 10, 2013 | Jan 05, 2016 | Patent |
| Anti-cancer therapies | Oct 23, 2012 | Dec 08, 2015 | Patent |
